privacy | investment disclaimer | contact us
Excorp Medical's Bioartificial Liver System comprises a reusable instrument, disposable tubing set and the proprietary, disposable bioartificail reactor.Once approved by regulatory agencies, Excorp Medical expects this breakthrough Bioartificial Liver System technology to be both live-saving and cost effective.Certain drugs or machines are available to substitute temporarily or long-term for many organs in the body…  no comparable substitute has been developed for the liver.The liver is the largest organ in the body and performs a variety of tasks impacting all body systems… as a result liver disease has widespread effects on virtually all other organs.Excorp Medical is currently the only company approved to conduct bioartificial liver human trials within the U.S.Currently patients must receive a liver transplant or endure prolonged hospitalization at great expense to have a chance at survival.Excorp Medical Bioartificial Liver System treatments serve as a bridge to liver regeneration and transplantExcorp Medical has developed a Bioartificial Liver System for the metabolic support of patients with compromised liver function.
Chinese Simplified
Chinese Traditional
Click below
for more info...
Pre-clinical Evaluation of Bioartificial Liver Support System
Plasma versus Whole Blood Perfusion
First Clinical Use of a Novel Bioartificial Liver Support
Clinical and laboratory evaluation of the safety
Bound Dilute Analysis
Oxygen Consumption in a Hollow Fiber Bioartificial Liver - Revisited

Bound Solute Dialysis

ASAIO Journal 2003
By John Patzer & Steve Benet


We used the thermodynamic principles governing bound solute dialysis, commonly referred to as "albumin dialysis" or "sorbent dialysis" and practiced clinically with the Molecular Adsorbent Recirculating System (MARS) and Biologic-DT approaches, respectively, to develop a comprehensive understanding of the process. Dimensionless parameters emerging from the thermodynamic analysis that govern bound solute dialysis are as follows: (1) , the binding power of the solute binding moiety; (2) , the dialyzer mass transfer/blood flow rate ratio; (3) , the dialysate/blood flow rate ratio; (4) , the dialysate/blood binding moiety concentration ratio, and (5) , the solute/binding moiety concentration ratio in the blood. Results from a mathematical model of countercurrent bound solute dialysis for = 0.9 indicate that for a given binding moiety (fixed ), the most important parameter for achieving high removal rates is the dialyzer mass transfer ratio for free (unbound) solute. The results also show solute removal approaching an asymptote with increasing that is dependent on and independent of . More importantly, results indicate that once a dialysis membrane is chosen, solute removal is virtually independent of blood flow rate, dialysate flow rate, and amount of binding moiety in the dialysate, provided the amount is greater than approximately 90% of that required to reach the asymptote. Experimental observations over a range of blood flow rates (100 - 400 ml/minute), dialysate flow rates (50 - 400 ml/minute), and dialysate/blood albumin concentration ratios ( = 0 - 0.3) corroborate the model predictions and indicate that < 4 g/L albumin in the dialysate solution is required for effective bound solute dialysis. The experimental results also show evidence of enhanced mass transfer once the dialysis membrane pore structure surface saturates with albumin. ASAIO Journal 2003; 49:271-281.

clinical trials
links & resources

©2014 Excorp Medical, Inc.